share_log

Achieva Medical Entered Into an Exclusive Distribution Agreement With NowYon Medical

Achieva Medical Entered Into an Exclusive Distribution Agreement With NowYon Medical

Achieva Medical已與NowYon Medical簽訂了獨家分銷協議
PR Newswire ·  08/28 04:40

SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiary, Achieva Medical Limited ("Achieva Medical"), entered into an exclusive distribution agreement with Jiangsu NowYon Medical Limited ("NowYon Medical"). The agreement marks a significant milestone in the expansion of Peijia Medical's Neurointerventional Business in the Greater China region.

中國蘇州,2024年8月28日 /美通社/ -- 中國領先的國內主要市場參與者佩佳醫療 (HKG:9996),宣佈旗下全資子公司艾維美爾有限公司 ("艾維美爾") 與江蘇諾永醫療有限公司 ("諾永醫療") 簽署了獨家分銷協議。該協議標誌着佩佳醫療在大中華區域神經介入業務擴張的重要里程碑。

Under the terms of the agreement, Achieva Medical has been appointed as the exclusive distributor for NowYon Medical's innovative YonFlow flow diverter, the first retrievable stent system after complete release globally. In January 2023, the product passed the innovative medical device review and was accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the National Medical Products Administration (NMPA). In addition, the application for the registration approval of YonFlow has been submitted to the NMPA, which is expected to be approved soon.

根據協議的條款,艾維美爾被任命爲諾永醫療創新的YonFlow分流器的獨家分銷商,該產品是全球首個可回收植入式支架系統。2023年1月,該產品通過了創新醫療器械審查,並獲得國家藥品監督管理局創新醫療器械專項審批程序的接受。此外,YonFlow的註冊批准申請已提交給國家藥品監督管理局,預計將很快獲得批准。

"This strategic collaboration with NowYon Medical is a testament to our commitment to bringing cutting-edge medical solutions to patients in need and will continue to consolidate our leading position in the neurovascular interventions market in China." said Dr. Yi Zhang, Chairman and CEO of Peijia Medical. "We are excited about the potential of the YonFlow flow diverter and its impact on improving patient outcomes."

佩佳醫療董事長兼首席執行官張毅博士表示:「與諾永醫療的戰略合作,證明了我們致力於將尖端醫療解決方案帶給有需求的患者,並將繼續鞏固我們在中國神經介入市場的領先地位。尤其我們對YonFlow分流器的潛力以及它對改善患者預後的影響感到興奮。」

About Peijia Medical
Peijia Medical (9996.HK) was established in 2012 and is headquartered in Suzhou, China. Peijia Medical focuses on the high-growth interventional procedural medical device market in China and aims to become a world-renowned medical device platform that provides comprehensive treatment solutions for structural heart and neurovascular diseases. The Company now has three TAVR systems and sixteen neurointerventional devices commercialized in China and various innovative product candidates at different stages of development.

關於佩佳醫療
佩佳醫療 (9996.HK) 成立於2012年,總部位於中國蘇州。佩佳醫療專注於中國高增長介入性手術醫療器械市場,併力爭成爲全球著名的醫療器械平台,爲結構性心臟病和神經血管疾病提供全面的治療方案。公司目前在中國商業化的有三個TAVR系統和十六種神經介入裝置,並有多個創新產品候選進展到不同的開發階段。

For more information about Peijia, please visit peijiamedical.com/about.

想了解更多關於佩佳的信息,請訪問peijiamedical.com/about。

About Achieva Medical
Achieva Medical, a wholly-owned subsidiary of Peijia Medical (9996.HK), is an innovative medical device company committed to development and manufacture of high-end neurointerventional medical devices. Achieva Medical now has sixteen commercialized products and various product candidates at different stage of development covering hemorrhagic stroke, ischemic stroke and vascular access.

關於成就醫療
成就醫療(9996.HK)是佩佳醫療的全資子公司,是一家致力於開發和製造高端神經介入醫療器械的創新型醫療器械公司。成就醫療目前已有十六種商品化產品,並有多種不同發展階段的產品候選品,涵蓋了出血性中風、缺血性中風和血管通路的解決方案。

About NowYon Medical
NowYon Medical is an innovative medical device company focusing on the development and manufacture of neurointerventional medical devices. Its product pipeline encompasses a range of solutions for hemorrhagic stroke, ischemic stroke and vascular access, including flow diverters, stent retrievers, aspiration catheters, balloon microcatheter, microcatheter, etc.

關於NowYon醫療
NowYon醫療是一家專注於開發和製造神經介入醫療器械的創新型醫療器械公司。其產品線包括一系列用於出血性中風、缺血性中風和血管通路的解決方案,包括轉流器、取栓器、抽吸導管、氣囊微導管、微導管等以太經典。

SOURCE Peijia Medical

培佳醫療

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論